BR112021022872A2 - Terapia de mic para imunosuppressão específica em transplante - Google Patents

Terapia de mic para imunosuppressão específica em transplante

Info

Publication number
BR112021022872A2
BR112021022872A2 BR112021022872A BR112021022872A BR112021022872A2 BR 112021022872 A2 BR112021022872 A2 BR 112021022872A2 BR 112021022872 A BR112021022872 A BR 112021022872A BR 112021022872 A BR112021022872 A BR 112021022872A BR 112021022872 A2 BR112021022872 A2 BR 112021022872A2
Authority
BR
Brazil
Prior art keywords
transplantation
specific immunosuppression
pharmaceutical compositions
mic
therapy
Prior art date
Application number
BR112021022872A
Other languages
English (en)
Inventor
Anita Schmitt
Caner Suesal
Christian Kleist
Christian Morath
Gerhard Opelz
Martin Zeier
Matthias Schaier
Michael Schmitt
Peter Terness
Volker Daniel
Original Assignee
Tolerogenixx Gmbh
Univ Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolerogenixx Gmbh, Univ Heidelberg filed Critical Tolerogenixx Gmbh
Publication of BR112021022872A2 publication Critical patent/BR112021022872A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A61K39/461—
    • A61K39/46434—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

a presente invenção diz respeito a composições farmacêuticas com células de sangue total ou células mononucleares do sangue periférico (pbmcs) isoladas e tratadas, assim como tais composições farmacêuticas para uso na prevenção e/ou tratamento de rejeição de enxerto de célula ou órgão em um receptor de enxerto humano.
BR112021022872A 2019-05-17 2019-05-17 Terapia de mic para imunosuppressão específica em transplante BR112021022872A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2019/062857 WO2020233776A1 (en) 2019-05-17 2019-05-17 Mic therapy for specific immunosuppression in transplantation

Publications (1)

Publication Number Publication Date
BR112021022872A2 true BR112021022872A2 (pt) 2021-12-28

Family

ID=66676482

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021022872A BR112021022872A2 (pt) 2019-05-17 2019-05-17 Terapia de mic para imunosuppressão específica em transplante

Country Status (16)

Country Link
US (1) US11554139B2 (pt)
EP (1) EP3784253B1 (pt)
JP (2) JP2022532786A (pt)
KR (1) KR20220035037A (pt)
CN (1) CN112351784A (pt)
AU (1) AU2019447492A1 (pt)
BR (1) BR112021022872A2 (pt)
CA (1) CA3139853A1 (pt)
ES (1) ES2973943T3 (pt)
HR (1) HRP20240311T1 (pt)
HU (1) HUE066195T2 (pt)
IL (1) IL288192A (pt)
PL (1) PL3784253T3 (pt)
RS (1) RS65322B1 (pt)
WO (1) WO2020233776A1 (pt)
ZA (1) ZA202108900B (pt)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2318020B1 (en) 2008-06-30 2015-08-19 Universitätsklinikum Heidelberg Immunosuppressive blood cells and methods of producing same
EP3018200A1 (en) * 2014-11-07 2016-05-11 Fondazione Matilde Tettamanti e Menotti de Machi Onlus Improved method for the generation of genetically modified cells
WO2018044789A1 (en) * 2016-08-29 2018-03-08 Progena, Inc. Autologous somatic stem cell therapy, method of controllable preparation of therapeutic composition and procedure of adaptive treatment of ivf patient
KR102147802B1 (ko) * 2018-11-07 2020-08-25 가톨릭대학교 산학협력단 신규 화합물 및 칼시뉴린 억제제를 포함하는 이식 거부 반응 또는 이식 거부 질환의 예방 및 치료용 조성물

Also Published As

Publication number Publication date
KR20220035037A (ko) 2022-03-21
PL3784253T3 (pl) 2024-05-13
JP2022532786A (ja) 2022-07-19
JP2024045215A (ja) 2024-04-02
AU2019447492A1 (en) 2021-12-09
WO2020233776A1 (en) 2020-11-26
HUE066195T2 (hu) 2024-07-28
EP3784253A1 (en) 2021-03-03
ES2973943T3 (es) 2024-06-25
EP3784253C0 (en) 2023-12-27
ZA202108900B (en) 2022-08-31
US11554139B2 (en) 2023-01-17
CN112351784A (zh) 2021-02-09
RS65322B1 (sr) 2024-04-30
US20220118009A1 (en) 2022-04-21
EP3784253B1 (en) 2023-12-27
IL288192A (en) 2024-03-01
CA3139853A1 (en) 2020-11-26
HRP20240311T1 (hr) 2024-05-10

Similar Documents

Publication Publication Date Title
PE20110358A1 (es) Metodos y composiciones para el tratamiento de defectos oseos con poblaciones de celulas placentarias
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
BR112018076306A2 (pt) composições e métodos para a supressão de células cd117+
MX2020005849A (es) Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos.
BR112018076263A2 (pt) composições e métodos para a depleção de células
BR112017010490A2 (pt) roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
MX2012011543A (es) Tratamiento de sarcoidosis empleando celulas madre placentarias.
BRPI0513477A (pt) composições e processos de uso de proteìna 4 semelhante a angiotensina
UY38389A (es) Dispositivos implantables para terapia celular y métodos relacionados
BR112021024822A2 (pt) Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência
WO2019118518A3 (en) Inducible cell receptors for cell-based therapeutics
EA201890782A1 (ru) Способ перенацеливания t-клеток для лечения инфекции hiv
BR112017026709A2 (pt) tratamento e diagnóstico de câncer
CL2008003063A1 (es) Compuestos derivados de 1,3,4-tiadiazol espiro condensado, inhibidores de la actividad quinesina ksp; composicion farmaceutica; y su uso en el tratamiento de enfermedades proliferativas tales como el cancer, hiperplasia, hipertrofia cardiaca, enfermedades autoinmune, trastornos fungicos, artritis, rechazo a imjertos, entre otras.
EA201790025A1 (ru) Создание банка мезенхимальных стромальных клеток из объединенных мононуклеарных клеток нескольких доноров костного мозга
WO2018053264A3 (en) Klrg1 depletion therapy
MX2023012918A (es) Agonistas del receptor del péptido 1 similar al glucagón (glp-1) de bencimidazoilo, composiciones farmacéuticas que los comprenden y métodos para su uso.
MX2020004806A (es) Composiciones y métodos para el agotamiento de células cd2+.
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
MX2023002542A (es) Anticuerpo biespecifico contra cumulo de difirenciacion 3 (cd3) y cumulo de difirenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes.
BR112022019060A2 (pt) Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
EA201591522A1 (ru) Лечение реакции трансплантат против хозяина у подвергаемых трансплантации пациентов
BR112021022872A2 (pt) Terapia de mic para imunosuppressão específica em transplante
PH12019500482A1 (en) Antibody for treating autoimmune diseases

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]